PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer

PARP inhibitors have shown promising clinical activities for patients with BRCA mutations and are changing the landscape of ovarian cancer treatment. However, the therapeutic mechanisms of action for PARP inhibition in the interaction of tumors with the tumor microenvironment and the host immune sys...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Liya, Kim, Hye-Jung, Wang, Qiwei, Kearns, Michael, Jiang, Tao, Ohlson, Carolynn E., Li, Ben B., Xie, Shaozhen, Liu, Joyce F., Stover, Elizabeth H., Howitt, Brooke E., Bronson, Roderick T., Lazo, Suzan, Roberts, Thomas M., Freeman, Gordon J., Konstantinopoulos, Panagiotis A., Matulonis, Ursula A., Zhao, Jean J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366450/
https://www.ncbi.nlm.nih.gov/pubmed/30540933
http://dx.doi.org/10.1016/j.celrep.2018.11.054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6366450/
https://www.ncbi.nlm.nih.gov/pubmed/30540933
http://dx.doi.org/10.1016/j.celrep.2018.11.054

Ejemplares similares